Bionano Genomics, Inc. 是一家基因组分析领域的生命科学仪器公司。公司总部位于加利福尼亚州圣地亚哥。
财务指标
营业收入
2026-06-30
$817.1万
2026-03-31
$668.7万
2025-12-31
$795.1万
2025-09-30
$736.7万
营业支出
2026-06-30
$1153.2万
2026-03-31
$1114.9万
2025-12-31
$1193.5万
2025-09-30
$1190.8万
净利润
2026-06-30
-$742.3万
2026-03-31
-$830.3万
2025-12-31
-$793.3万
2025-09-30
-$850.3万
净利润率
2026-06-30
-90.84%
2026-03-31
-124.16%
2025-12-31
-99.77%
2025-09-30
-115.42%
每股收益
2026-06-30
$-0.64
2026-03-31
$-0.75
2025-12-31
$-0.03
2025-09-30
$-1.59
息税折旧摊销前利润
2026-06-30
-$512万
2026-03-31
-$586万
2025-12-31
-$543.8万
2025-09-30
-$599.3万
有效税率
2026-06-30
-0.09%
2026-03-31
-0.12%
2025-12-31
-0.44%
2025-09-30
-0.16%
项目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
营业收入
$817.1万
$668.7万
$795.1万
$736.7万
营业支出
$1153.2万
$1114.9万
$1193.5万
$1190.8万
净利润
-$742.3万
-$830.3万
-$793.3万
-$850.3万
净利润率
-90.84%
-124.16%
-99.77%
-115.42%
每股收益
$-0.64
$-0.75
$-0.03
$-1.59
息税折旧摊销前利润
-$512万
-$586万
-$543.8万
-$599.3万
有效税率
-0.09%
-0.12%
-0.44%
-0.16%
常见问题
BNGO stock represents ownership shares in Bionano Genomics, Inc., a company that develops and markets genome analysis solutions. Its platform includes optical genome mapping and software for researchers and clinical labs. BNGO trades on the Nasdaq Capital Market under the ticker BNGO. The stock gives investors exposure to the life sciences tools and genomics sector, though the company is not currently profitable and carries the risks typical of smaller, research-driven biotechnology firms.
Start with Bionano Genomics' investor relations page for SEC filings such as 10-K and 10-Q reports, press releases, and earnings call transcripts. Review the company's revenue trends, gross margins, cash burn, and balance sheet. Track news about product adoption, reimbursement, and competitive developments in genome analysis. For market data like the current BNGO quote, market cap, and trading volume, use the latest figures displayed on this page rather than relying on older sources.
BNGO is influenced by company-specific developments such as quarterly revenue, cash position, product launches, and regulatory or reimbursement news. Broader forces include competition in genomics, research funding levels, and changes in Medicare or insurance coverage for genetic testing. As a small-cap stock, it can also react sharply to shifts in investor sentiment, interest rates, and general market conditions. Monitoring both business fundamentals and sector trends helps explain BNGO's price movements.
No single metric definitively answers whether BNGO is overvalued or undervalued. Bionano Genomics is not consistently profitable, so a P/E ratio may be unavailable or not meaningful. Investors often compare enterprise value to revenue, price-to-sales, and cash runway against peers in life sciences tools. Because those figures change with the market, check the latest BNGO valuation data shown on this page and weigh it against the company's growth prospects and risks.
BNGO can be traded in pre-market and after-hours sessions through many brokers, but these extended-hours sessions have lower liquidity, wider spreads, and higher volatility than regular trading. U.S. regular hours for Nasdaq-listed stocks are typically 9:30 a.m. to 4:00 p.m. Eastern Time. Not all brokers offer pre-market or after-hours trading, and orders may not execute if there is insufficient volume, so check your broker's specific policies before trading BNGO outside regular hours.
There is no fixed minimum for BNGO itself; the practical requirement is enough cash to buy at least one share at the current market price. Many brokers also offer fractional shares, allowing you to invest a smaller dollar amount. Some brokers have account minimums or charge commissions, while others offer commission-free stock trading. Check the latest BNGO price on this page and your broker's fee schedule to estimate the amount needed for a single trade.